T/PTO 1 5 OCT 2004 DT05 Rec'd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Jose Luis Castro Pineiro et al.

Serial No.:

To Be Assigned

Case No.: T1573P

Filed:

Int'l Appl'n No.

PCT/GB03/01758

Int'l Filing Date: 24 April 2003

For:

ALKENYL-SUBSTITUTED SPIROCYCLIC SULFAMIDES AS

INHIBITORS OF GAMMA-SECRETASE

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT OYOUR EXPRESS MAIL NO. EVADIS

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1459

MAILED BY

Int'l Appl'n No.: PCT/GB03/ Case No.: Page

DT05 Rec'd PCT/PT0 1 5 OCT 2004'

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Copies of the non-U.S. patent documents that are cited on the attached form PTO-1449 are enclosed herewith.

All the references cited on the attached form were cited in the International Search Report for this application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

John C. Todaro, Reg. No. 36,036

Attorney for Applicant

MERCK & CO., Inc. P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0125

Date: Oldober 15, 2004

DT05 Rec'd POT/PT06. ONB 5.8 QGT 2004
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Si	ubstitute for form 1449A/PTO			COMPLETE I			
	NFORMATION 1	DIS	CLOSURE	Application Number	To Be Assigned 1 0 / 511 5 0 7		
c	STATEMENT BY	A D	DI ICANT	Filing Date			
3	OIAIEMENI BY	AP	PLICANI	First Named Inventor	Jose Luis Castro Pineiro et al.		
				Group Art Unit	To Be Assigned		
	(use as many sheets	as n	iecessary)	Examiner Name	To Be Assigned		
Sheet	1	of	2	Attorney Docket Number	T1573P		

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		-			
					-
					·

			FORE	GN PATENT	T DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Patent Documer Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
			WO 02/36555	(if known) PCT	Merck Sharp & Dohme Limited	05/10/2002
			WO 01/70677	PCT	Merck Sharp & Dohme Limited and	
					Merck Frosst Canada & Co.	09/27/2001
					Data	

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DT05 Rec'd PCT/PT0 1 5 OCI 2004

Approved for use through 7/31/2006. OMB 0651-0031

SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

<u> </u>		- fa 4.440D/DTO				COMPLETE I OWN
		r form 1449B/PTO RMATION	N DIS	CLOSURE	Application Number	To Be Assigned 7 1511507
,	ION A ONT	מו ידיו אינו אינו	37 A D	DIICANT	Filing Date	
) 3	IAII	FIMIFINI B	Y AF	PLICANT	First Named Inventor	Jose Luis Castro Pineiro et al.
	,	,			Group Art Unit	To Be Assigned
	(use	as many shee	ets as n	iecessary)	Examiner Name	To Be Assigned
Sheet	-	2	of	2	Attorney Docket Number	T1573P

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		G. M. Rishton et al., "Fenchylamine Sulfonamide Inhibitors of Amyloid Beta Peptide Production by the Gamma-Secretase Proteolytic Pathway", J. Med. Chem., 2000, 43, 2297-2299

Examiner Date Considered
